Acadia Pharmaceuticals (NASDAQ:ACAD) announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive
Summary: Shares of Acadia trended lower this year due to Daybue’s poor quarterly sales performance,
LeoPatrizi Despite ACADIA Pharmaceuticals’ (NASDAQ:ACAD) Q2 beat yesterday, Morgan Stanley downgraded the stock on Wednesday,
Acadia Pharma press release (NASDAQ:ACAD): Q2 GAAP EPS of $0.20 beats by $0.03. Revenue of
Acadia Pharma (NASDAQ:ACAD) is scheduled to announce Q2 earnings results on Tuesday, August 6th, after
Summary: Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to
Summary: ACADIA Pharmaceuticals is a biopharmaceutical company specializing in CNS disorder treatments, with two successful
jittawit.21 Cantor Fitzgerald has selected its 14 top picks for biotech stocks that it regards
Acadia Pharma press release (NASDAQ:ACAD): Q1 GAAP EPS of $0.10 beats by $0.05. Revenue of
Acadia Pharma (NASDAQ:ACAD) is scheduled to announce Q1 earnings results on Wednesday, May 8th, after